AGS Therapeutics Strengthens its Patent Portfolio on Microalgae Extracellular Vesicles (MEV) with an International Patent Application on MEVs from Genetically Modified Microalgae Containing Endogenously-Loaded Payloads
MEVs are a universal delivery system; suitable for delivering innovative therapeutics, vaccines and gene therapies. MEVs can be administered through multiple routes; they overcome stringent biological barriers and reach difficult-to-access tissues, providing the potential to overcome challenges faced by other delivery systems. MEVs deliver their payload in target tissues of interest, where the payload elicits its desired biological activity. MEVs can be exo-loaded or endo-loaded with a diversity of payloads or therapeutic modalities.
PARIS, FRANCE, January 17, 2024 – AGS Therapeutics, a preclinical-stage biotech company pioneering microalgae extracellular vesicles (MEV) as a new, universal delivery system, announced the recent publication of its PCT Application No. PCT/EP2023/064751 - Publication - WO2023/232976A1, titled Extracellular Vesicles from Genetically-Modified Microalgae Containing Endogenously-Loaded Cargo, their Preparation, and Uses.
MEVs can be used to deliver their payloads to various specific tissues and organs, which have been so far either difficult or impossible to access by current alternative systems like LNPs, viral gene therapy vectors, or mammalian EVs.
The published patent application highlights the potential to genetically-engineer the microalgae cells to produce functionalized MEVs with specific payloads or surface markers.
“MEVs bear a natural tropism to specific cells and tissues, and a natural capacity to overcome certain stringent biological barriers, which makes them perfectly suited as a delivery system for a large number of therapeutic modalities and approaches without the need of engineering their surface or functions. The possibility to engineer the microalgae to produce functionalized MEVs broadens the repertoire of potential where MEVs can make a significant difference when compared with other delivery systems”, said AGS Chief Operating Officer Lila Drittanti.
AGS’ portfolio of Intellectual Property is managed by Stephanie Seidman, at Womble Bond Dickinson, San Diego (www.womblebonddickinson.com/us/people/stephanie-seidman).
AGS Therapeutics, based in Paris, France, is a biotech company pioneering the use of extracellular vesicles from microalgae (MEV) as a universal delivery system for innovative biologics and gene therapies. AGS has shown MEVs to be a safe, targeted and highly versatile delivery system for mRNA, siRNA, DNA, plasmids, and proteins relevant to a broad range of human diseases. AGS-M, a company’s subsidiary and a contract development and manufacturing organisation, will produce the MEVs needed to support preclinical and clinical development of product pipelines from AGS and from pharmaceutical companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae, labelled by FDA as GRAS for consumption as a food suplement. AGS’ MEVs are easy to manufacture in large quantities with processes that are both eco-friendly and easily scalable. Through strategic partnerships and a commitment to scientific excellence, the company aims to challenge the delivery landscape and improve the lives of patients across the globe. For more information visit www.ags-tx.com and www.ags-m.com.
Forward looking statement
This announcement may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this communication.
+33 (0)6 07 16 55 01
Markets @ Listing
+33 (0)6 88 57 05 77